Cullinan Therapeutics, Inc. (CGEM) Institutional Ownership

Ownership Summary

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) is held by 150 institutional investors per 13F filings through December 2025.

• They owned 111.0% of outstanding stock in December 2025, up from 104.6% the prior quarter.
• They increased total shares held in CGEM by 12.8% quarter over quarter, and investors in Cullinan Therapeutics increased 1.35% from a year ago.
• Of these 150 holders, 94 added to their stakes in Cullinan Therapeutics, 39 trimmed positions, and 17 made no changes.
• Combined, these investors held 65.55Mn shares in CGEM for December 2025, up by 7.44Mn shares quarter on quarter, and down 1.4Mn shares year over year.
• Lynx1 Capital Management LP is the top holder of Cullinan Therapeutics as of December 31, 2025, with 8.96Mn shares representing 15.17% of outstanding stock.
• The most significant purchases of CGEM for the quarter ending December 2025 came from Lynx1 Capital Management LP (3.2Mn), Blue Owl Capital Holdings LP (2.19Mn), Affinity Asset Advisors, LLC (1.67Mn), BOOTHBAY FUND MANAGEMENT, LLC (1.24Mn), Kynam Capital Management, LP (811.96K).
• The largest sellers of Cullinan Therapeutics for the quarter ending December 2025 were DEERFIELD MANAGEMENT COMPANY, L.P. (2.54Mn), CITADEL ADVISORS LLC (1.87Mn), ORBIMED ADVISORS LLC (1.65Mn), Bank Of America Corp /De/ (768.07K), DIMENSIONAL FUND ADVISORS LP (335.05K).
• Per Business Quant, the top 10 investors in CGEM for the quarter ending December 2025 include Lynx1 Capital Management LP (8.96Mn), MPM BioImpact LLC (7.65Mn), BVF INC/IL (5.75Mn), Blue Owl Capital Holdings LP (4.7Mn), BlackRock, Inc. (4.4Mn), VANGUARD GROUP INC (3.3Mn), Kynam Capital Management, LP (3.11Mn), State Street Corp (2.2Mn), Affinity Asset Advisors, LLC (1.93Mn), RTW INVESTMENTS, LP (1.71Mn).